Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Distribute Axxam's GPCR Screening Platform; Firms to Create Joint R&D Program

NEW YORK (GenomeWeb News) — PerkinElmer said today it will distribute to drug companies worldwide a luminescent cell-based assay made by Italian company Axxam.
The companies also agreed to create a joint R&D program to develop Photina GPCR and ion-channel lines to profile compounds and in high-throughput screening studies.
PerkinElmer said terms of the deal call for it to distribute the Photina photoprotein system, which is used to screen drug-discovery targets such as G-protein coupled receptors and ion channels.
The deal allows Axxam to continue to use Photina in its own drug-development service to third-party clients, the company said.
PerkinElmer said the agreement with Axxam enhances the capabilities it gained through its December acquisition of Euroscreen products and its own AequoScreen cellular assay platform.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.